Navigation Links
Healthcare Industry Leader Virginia Rybski Remembered
Date:5/13/2013

SCOTTSDALE, Ariz., May 13, 2013 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company focused on tissue regeneration, announced today that CEO Virginia Rybski lost her battle with pancreatic cancer.  Virginia was compassionately dedicated to her family, colleagues, patients and faith.

(Photo:  http://photos.prnewswire.com/prnh/20130513/LA13153)

(Logo:  http://photos.prnewswire.com/prnh/20120109/LA31405LOGO)

"We celebrate the privilege to have worked with such a talented leader, who was the driving force behind Regenesis' success," said John Voris , Chairman of the Board of Directors.  "Virginia's legacy includes a capable and dedicated management team that remains intact.  They are committed to achieving her vision of reaching patients in need of pain relief with the Provant® Therapy System."  

Ms. Rybski served Regenesis most recently as President, Chief Executive Officer and Board Director.  She combined 35 years experience founding and building emerging bioscience companies, by developing and commercializing numerous advanced-technology healthcare products.  Virginia earned a Bachelor of Arts in Molecular Biology from the University of North Carolina, and a Masters in Hospital Administration from the University of Phoenix.  She served on the Board of Directors for AdvaMed, the advanced medical technology association, as well as serving on the Emerging Growth Company Council, the Payment Advisory Work Group, and the Wound Sector Group.  She also served on the Board of Directors for AZBIO, the Arizona biotechnology and medical device association.

Virginia is survived by her husband Tom, and daughters Savannah and Olivia.  Her family provided the opportunity to support pancreatic research, through the Pancreatic Cancer Action Network at https://netcommunity.pancan.org/sslpage.aspx?pid=218

Regenesis will soon make an announcement regarding the CEO succession plan.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products.  Regenesis developed, patented, and now markets the Provant Therapy System.  Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and outpatient clinics.

About the Provant® Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

Contact: Regenesis Biomedical, Inc.
Scott Robey , Vice President Marketing
www.regenesisbio.com
480-970-4970 phone


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CitiusTechs BI-Clinical Platform for Healthcare BI & Analytics Receives NCQA HEDIS Certification
2. Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference
3. Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
4. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
5. Healthcare Corporation of America Sets Date for Release of its First-Quarter Results and Conference Call
6. Bayer Employee Named Rising Star by Healthcare Businesswomens Association
7. Maxim Healthcare Services Names National Caregiver of the Year Winner
8. Allied Healthcare Products Reports Loss On Depressed Sales
9. BidMed Awarded Equipment Liquidation and Related Services Agreement with the Premier Healthcare Alliance
10. Millennium HealthCare Signs Exclusive Distribution Agreement with Heart Smart Inc.
11. Cynosure to Present at UBS Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):